Portola Pharmaceuticals Inc. said William Lis will retire as CEO and board member Aug. 1.
Lis, who joined the South San Francisco, Calif.-based Portola in 2008, will remain with the company in an advisory role after retirement.
The company has initiated a search to find a suitable replacement.
Executive Vice President John Curnutte and CFO Mardi Dier will serve as co-presidents in addition to their current roles on an interim basis.
Portola is a biopharmaceutical company that develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders and inflammation.
